Compare TOMZ & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | VTGN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9M | 9.5M |
| IPO Year | 2009 | 2014 |
| Metric | TOMZ | VTGN |
|---|---|---|
| Price | $1.91 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 25.2K | ★ 846.7K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $111.80 | $33.96 |
| Revenue Next Year | $52.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.21 | $0.17 |
| 52 Week High | $9.73 | $5.14 |
| Indicator | TOMZ | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 29.12 |
| Support Level | $1.28 | N/A |
| Resistance Level | $1.95 | $0.32 |
| Average True Range (ATR) | 0.20 | 0.01 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 80.24 | 6.37 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.